Study finds increase in GLP-1RA prescriptions to treat obesity but reduced for T2DM
An investigation led by researchers at Cedars-Sinai Medical Center and other institutions conducted a US-wide, population-based study to...
top of page
Browse by category
Search
Innovent’s DREAMS-1 trial of mazdutide GLP-1R and GCGR dual agonist meets study endpoints
Innovent Biologics’ Phase 3 clinical trial (DREAMS-1) of mazdutide a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor...
Roche’s oral GLP-1 receptor agonist CT-996 has weight loss of -6.1% within four weeks
Roche has reported positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational,...
Journal Watch 17/7/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
AI analysis finds huge public interest in GLP-1 drugs for weight loss and mental health benefits
Using a large language models (LLMs) to analyse over 391,000 unique discussions related to glucagon-like peptide-1 (GLP-1) receptor...
SH2B1 gene mutation play an important role in regulating food intake
Researchers from the University of Michigan have identified where a gene called SH2B1 is acting inside the paraventricular hypothalamus...
Harnessing network of CNS proteins could increase effectiveness of GLP-1s
A network of proteins found in the central nervous system could be harnessed to increase the effectiveness and reduce the side effects of...
First patient enrolled in a Phase 2 Study in T2DM patients with Olatec's NLRP3 inhibitor dapansutrile
The first patient with T2DM and diabetes-related complications has been enrolled in the clinical trial, DAPAN-DIA, in Basel, Switzerland,...
EMA issues recommendations for GLP-1ra to minimise risk of aspiration and pneumonia aspiration during general anaesthesia or deep sedation
European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended new measures to minimise the risk of...
Amylyx acquires avexitide GLP-1ra post-bariatric hypoglycaemia from Eiger BioPharmaceuticals
Amylyx Pharmaceuticals has acquired avexitide from Eiger BioPharmaceuticals, an investigational, first-in-class glucagon-like peptide-1...
Browse by tag
bottom of page